


CLAIMS

Pursuant to 37 C.F.R. § 1.121(c)(1), please amend claims 24, 47, and 51 as set forth below:

Claims 1-23 (Cancelled)

24. **(Currently Amended)** A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand:

W represents S, N, or P;

Y represents -OR7, -SR7, a halogen or -N(R9)R10;

R9 and R10, each independently, represent -H, alkyl, alkenyl, $-(CH_2)_n-R7$, or R9 and R10, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R7 represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle;

wherein the ligand V comprises a heterocycle, optionally aromatic and optionally substituted, that comprises the atoms W and Y and has from 4 to about 8 atoms in the ring structure.

25. **(Original)** The coordination complex of claim 24, wherein W is N.

26. **(Original)** The coordination complex of claim 24, wherein Pt is Pt(II).

27. **(Original)** A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 24 and a pharmaceutically acceptable carrier.

28. **(Original)** The pharmaceutical composition of claim 27, wherein said coordination complex is ammine(2-amino-3-picoline)dichloroplatinum(II).

Claims 29-32 (Cancelled)

33. **(Previously Presented)** The coordination complex of claim 24, wherein V is a 6-membered aromatic heterocycle.

34. **(Previously Presented)** The coordination complex of claim 33, wherein V is pyridine or a substituted pyridine.

35. **(Previously Presented)** The coordination complex of claim 33, wherein V is picoline or a substituted picoline.

36. **(Previously Presented)** The coordination complex of claim 24, wherein Pt is Pt(IV) and two additional ligands in the trans axial positions are present.

37. **(Previously Presented)** The coordination complex of claim 36, wherein said each of said additional ligands comprise a carboxylate group.

38. **(Previously Presented)** A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 36 and a pharmaceutically acceptable carrier.

39. **(Previously Presented)** The pharmaceutical composition of claim 38, wherein said coordination complex is ammine(2-amino-3-picoline)dichlorodiacetoplatinum(IV).

40. **(Previously Presented)** The coordination complex of claim 24, wherein both X are halogens.

41. **(Previously Presented)** The coordination complex of claim 40, wherein said halogen is chlorine.

42. **(Previously Presented)** The coordination complex of claim 24, wherein both X comprise a carboxylate group.


43. **(Previously Presented)** The coordination complex of claim 42, wherein said carboxylate group is a chelating dicarboxylate.

44. **(Previously Presented)** The coordination complex of claim 42, wherein at least one X is acetate.

45. **(Previously Presented)** The coordination complex of claim 24, wherein L is an amine having the structure $\text{NR}_2(\text{R}_3)$, wherein R_2 and R_3 each independently represent a hydrogen, an alkyl, an alkenyl, $-(\text{CH}_2)_m-\text{R}_4$, or R_2 and R_3 , taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; and wherein R_2 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8.

46. **(Previously Presented)** The coordination complex of claim 24, wherein L is an ammine.

47. **(Currently Amended)** A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents $-\text{OR}_7$, $-\text{SR}_7$, a halogen or $-\text{N}(\text{R}_9)\text{R}_{10}$;

R_9 and R_{10} , each independently, represent $-\text{H}$, alkyl, alkenyl, $-(\text{CH}_2)_n-\text{R}_7$, or R_9 and R_{10} , taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R_7 represents $-\text{H}$, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle;


wherein the ligand V comprises a heterocycle, optionally aromatic and optionally substituted, that comprises the atoms W and Y and has from 4 to about 8 atoms in the ring structure.

48. **(Previously Presented)** The coordination complex of claim 47, wherein each of X is a halogen.

49. **(Previously Presented)** The coordination complex of claim 48, wherein said halogen is chlorine.

50. **(Previously Presented)** A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 47 and a pharmaceutically acceptable carrier.

51. **(Currently Amended)** A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents -OR₇, -SR₇, a halogen or -N(R₉)R₁₀;

R₉ and R₁₀, each independently, represent -H, alkyl, alkenyl, -(CH₂)_n-R₇, or R₉ and R₁₀, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R₇ represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle;

wherein the ligand V comprises a heterocycle, optionally aromatic and optionally substituted, that comprises ~~the atoms~~ W and Y and has from 4 to about 8 atoms in the ring structure.

52. **(Previously Presented)** A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 51 and a pharmaceutically acceptable carrier.